Effects of Daying tablet add-on risperidone on plasma neurotransmitter of schizophrenia
Abstract：Objective To explore the effects of Daying tablet add-on risperidone on plasma neurotransmitter in the treatment of schizophrenia and its correlation analysis. Methods A randomized double-blind controlled study was applied. A total of 67 patients meeting the criteria of ICD-10 for schizophrenia were randomly divided into the Daying tablet group (n=30) and the placebo group (n=37). The participants were treated with Daying tablet add-on risperidone and Daying combined placebo tablet respectively for 12 weeks. The level of dopamine(DA), 5-hydroxytryptamine (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) were measured before and after treatment, at the same time the Positive and Negative Syndrome Scale (PANSS) was applied to evaluate curative effect. Results After treatment, plasma levels of DA and 5HIAA decreased, and 5-HT increased in the Daying tablet group, while all the measured neurotransmitters of the placebo group decreased. There was no significant difference between the two groups after the treatment (P>0.05). In addition, there was no significant correlation between changes of measured neurotransmitter concentration and the curative effect. Conclusions The changes of plasma neurotransmitters (including DA, 5-HT and 5-HIAA) have no significant difference between the Daying combined with risperidone group and the placebo group in schizophrenia patients, and there is no significant correlation with efficacy.
Keywords：Daying tabletSchizophreniaDopamine5-hydroxytryptamine5-hydroxyindole-acetic acld
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 702-704 )